TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05265273: A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Sponsor: Janssen Research & Development, LLC · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,673,264

Rescue Site Savings

+$1,782,176

Unlock Full NCT05265273 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05265273 Rescue Dossier →